NCT01902251View on ClinicalTrials.gov

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Prostate CancerPharmacokinetics of Enzalutamide
Interventions
DRUG

Enzalutamide tablet

Oral

DRUG

Enzalutamide capsule

Oral

Trial Locations (4)

15232

University of Pittsburgh Medical Center, Pittsburgh

60637

University of Chicago Medical Center, Chicago

78229

South Texas Accelerated Research Therapeutics, San Antonio

80045

University of Colorado - Anschutz Medical Campus, Denver

Sponsors

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01902251 - Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | Biotech Hunter | Biotech Hunter